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Gene/pathway-based methods are drawing significant attention
due to their usefulness in detecting rare and common variants that
affect disease susceptibility. The biological mechanism of drug re-
sponses indicates that a gene-based analysis has even greater poten-
tial in pharmacogenetics. Motivated by a study from the Vitamin
Intervention for Stroke Prevention (VISP) trial, we develop a gene-
trait similarity regression for survival analysis to assess the effect of a
gene or pathway on time-to-event outcomes. The similarity regression
has a general framework that covers a range of survival models, such
as the proportional hazards model and the proportional odds model.
The inference procedure developed under the proportional hazards
model is robust against model misspecification. We derive the equiv-
alence between the similarity survival regression and a random effects
model, which further unifies the current variance component-based
methods. We demonstrate the effectiveness of the proposed method
through simulation studies. In addition, we apply the method to the
VISP trial data to identify the genes that exhibit an association with
the risk of a recurrent stroke. The TCN2 gene was found to be asso-
ciated with the recurrent stroke risk in the low-dose arm. This gene
may impact recurrent stroke risk in response to cofactor therapy.
1. Introduction. Genetic variations play a significant role in drug re-
sponses. A gene that participates in a particular physiological mechanism
might influence the response to a specific therapeutic agent that targets
the mechanism. Identifying these influential genes may help to clarify if an
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individual might benefit from or be harmed by the therapy. Understand-
ing the genetic diversity of drug responses can help to identify medications
that maximize treatment effectiveness and minimize the risk of adverse ef-
fects for individuals. Such an understanding will also lead to improved risk
stratification, prevention and treatment strategies for human diseases. Phar-
macogenetics studies show how an adverse reaction or positive response to
pharmaceutical treatment is affected by an individual’s genetic makeup and
has the potential to deliver both public health and economic benefits rapidly.
With the recent advancements in high-throughput technologies, it is becom-
ing common for pharmacogenetic researches to systematically investigate
genetic markers across the genome. Nevertheless, appropriate and efficient
analysis of the data remains a challenge.
Gene- or pathway-based analyses can assess pharmacogenetic effects more
effectively than single-marker based analyses [Goldstein, Tate and Sisodiya
(2003); Goldstein (2005)]. First, there often exist obvious candidate genes
and pathways that metabolize the drug and carry variants that are relevant
to the drug responses. Responses to therapies usually involve complex re-
lationships between gene variants within the same molecular pathway or
functional gene set. When applied to pharmacogenetic studies, gene- or
pathway-based methods might identify multiple variants of subtle effects
that are missed by single marker-based methods. Second, pharmacogenetic
studies typically enroll only a moderate number of patients, which limits the
power of the association detection. Gene-based analyses have been shown
to yield higher power than standard single marker and haplotype analyses.
This type of analysis can particularly facilitate studies on rare-event drug re-
sponses, such as adverse reactions, where it could take many years to collect
a sufficient number of samples to obtain adequate power for standard anal-
yses. In gene-based analyses, the association signals are aggregated across
variants, and the total number of tests is reduced; the amplification of the
association signals and the alleviation of the multiple testing burdens result
in improved power.
Our study was motivated by the need for a gene-based analysis of the time-
to-event data of the Vitamin Intervention for Stroke Prevention (VISP) trial
[Toole, Malinow and Chambless (2004); Hsu, Sides and Mychalecky (2011)].
Our goal is to assess the association between the recurrent stroke risk and the
9 candidate genes involved in the homocystein (Hcy) metabolic pathway (see
Data section for more details). In our preliminary analysis, we used the Cox
proportional hazards (PH) model [Cox (1972)] to perform single-SNP screen-
ing on 69 SNPs across 9 genes from 969 individuals. There were no SNPs past
the significance threshold after accounting for multiple testing. However, the
top 6 hits, thresholding at unadjusted p-values <0.05, were concentrated in
two genes. Specifically, 4 SNPs are from TCN2 (i.e., rs1544468, rs731991,
rs2301955 and rs2301957 have Wald’s test p-values of 0.0065, 0.0072, 0.0346
SIMILARITY REGRESSION FOR SURVIVAL OUTCOMES 3
Fig. 1. The Kaplan–Meier survival curves for the top 6 SNPs identified from the single
SNP association analysis with risk of recurrent stroke.
and 0.0346, resp.) and 2 SNPs are from CTH (i.e., rs648743 and rs663465
each have a Wald’s test p-value of 0.0115). The Kaplan–Meier curves of these
6 SNPs are shown in Figure 1 and indicate the potential for different risk
patterns among different variants at these loci. The clustering within the
two genes suggests that it would be more efficient to combine the individual
signal strengths and model the joint effect of multiple loci in a gene.
We perform the gene-based analysis using a gene-trait similarity regres-
sion inspired by Haseman–Elston regression from linkage analysis [Elston
et al. (2000); Haseman and Elston (1972)] and haplotype similarity tests
for regional association [Beckmann et al. (2005); Qian and Thomas (2001);
Tzeng et al. (2003)]. First, we quantify the genetic and trait similarities for
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each pair of individuals. The genetic similarity is determined using identity
by state (IBS) methods. The trait similarity is obtained from the covariance
of the transformed survival time conditional on the covariates. We then
regress the trait similarity on the genetic similarity and test the regression
coefficient to detect the genetic association. There are several gene-based ap-
proaches for censored time-to-event phenotypes in the literature, including
Goeman et al. (2005) and Lin and colleagues [Cai, Tonini and Lin (2011);
Lin et al. (2011)]. In these approaches, the multimarker effects were modeled
under the Cox PH model using linear random effects [Goeman et al. (2005)]
or a nonparametric function induced by a kernel machine [Cai, Tonini and
Lin (2011); Lin et al. (2011)]. The global effect of a gene was detected by
testing for the corresponding genetic variance component. These approaches
were found to be superior in identifying pathways or genes that are associ-
ated with survival.
For many years, similarity-based methods have been successfully used to
evaluate gene-based associations in quantitative and binary traits [Beck-
mann et al. (2005); Lin and Schaid (2009); Qian and Thomas (2001); Tzeng
et al. (2003); Wessel and Schork (2006)]. Our work makes such approaches
available for survival phenotypes. In addition, our similarity regression cov-
ers a variety of risk models, including the commonly used PH model and the
proportional odds (PO) model. Furthermore, we show that the coefficient of
the similarity regression obtained for survival phenotypes can be reexpressed
as a variance component of a certain working random effects model. Such
results facilitate the derivation of the test statistic and unify the similar-
ity model and previous variance component methods [Goeman et al. (2005);
Cai, Tonini and Lin (2011); Lin et al. (2011)]. Specifically, under the Cox PH
model, our test statistic is equivalent to the test statistic defined by a kernel
machine approach [Lin et al. (2011)]. We also show that the test statistic
can be robust to model misspecification. Specifically, the proposed test gives
the correct type I error even if the true risk model is misspecified. However,
the correct specification of the true risk model generally leads to a test with
better power. Finally, we demonstrate the utility of the similarity regression
by identifying the important TCN2 gene in the VISP study. The signifi-
cance of TCN2 to stroke risk has been reported by other association studies
[Giusti et al. (2010); Low et al. (2011)] and has been supported by molecular
biology evidence [Afman et al. (2003); von Castel-Dunwoody et al. (2005)].
Our findings further suggest potential interactions between TCN2 and B12
supplementation. This new information furthers the possibility that TCN2
could be utilized to predict recurrent strokes, identify at-risk individuals and
identify therapeutic targets for ischemic stroke.
2. Data. The VISP study was a prospective, double-blind, randomized
clinical trial [Toole, Malinow and Chambless (2004)]. The trial was designed
to study if high doses of folic acid, vitamin B6 and vitamin B12 reduce the
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risk of a recurrent stroke as compared to low doses of these vitamins. The
trial enrolled patients who were 35 or older, had a nondisabling cerebral
infarction within 120 days of randomization, and had Hcy levels in the top
quartile of the U.S. population. Subjects were randomly assigned to receive
daily doses of either a high-dose formulation (containing 25 mg vitamin B6,
0.4 mg vitamin B12 and 2.5 mg folic acid) or a low-dose formulation (con-
taining 200 µg vitamin B6, 6 µg vitamin B12 and 20 µg folic acid). Patient
recruitment began in August 1997 and was completed in December 2001. A
total of 3680 participants were enrolled at 56 clinical sites across the United
States, Canada and Scotland. The patients were followed for a maximum of
two years, and the average follow-up duration was 1.7 years. In the VISP
genetic study, 2206 participants provided informed consent and blood sam-
ples. The SNP genotypes of 9 genes related to the enzymes and cofactors in
the Hcy metabolic pathway were collected: BHMT1, BHMT2, CBS, CTH,
MTHFR, MTR, MTRR, TCN1 and TCN2 [Hsu, Sides and Mychalecky
(2011)]. In a previous study, Hsu, Sides and Mychalecky (2011) conducted
single-SNP analyses on targeted loci (e.g., Hcy-associated variants) to ex-
amine the genetic association with the recurrent stroke risk. In the low-dose
arm, the authors found that TCN2 SNP rs731991 under a recessive mode
was associated with the risk of a recurrent stroke with an unadjusted log-
rank test p-value of 0.009. The associations for the remaining SNPs within
the 9 genes in the low-dose arm were not studied. We extend this previous
analysis to all 9 genes using a gene-based approach. After quality control
screening of the data (e.g., removing loci with >99% missing proportion or
Hardy–Weinberg disequilibrium under additive mode and removing individ-
uals with missing genotypes), the analysis included 969 individuals in the
low-dose arm with 69 recessively coded SNPs.
3. Gene-trait similarity regression for survival traits.
3.1. The model. For individual i (i = 1,2, . . . , n), let Ti denote the sur-
vival time of interest and Ci denote the censoring time. We observe T˜i =
min(Ti,Ci) and the censoring indicator δi = I(Ti ≤ Ci). In addition, let Xi
denote the K× 1 vector of covariates and gmi denote the allele count vector
of marker m for person i, where the length of gmi, ℓm is the number of
distinct alleles at marker m, m = 1,2, . . . ,M . For example, for a tri-allelic
locus m, gmi = (1,0,1)
T if person i has genotype “A1A3” and (0,2,0)
T if
person i has genotype “A2A2.”
For each pair of individuals i and j, we measure the genetic similarity,
Sij , of the targeted gene and the trait similarity, Zij . The genetic simi-
larity is quantified using the weighted IBS sum across the M markers in
the gene, that is, Sij =
∑M
m=1wmS
m
ij , where S
m
ij = 2 if |gm,i − gm,j | is a
zero vector, Smij = 1 if |gm,i −gm,j | contains exactly two 1’s (and if ℓm > 2,
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the remaining entries are 0), and Smij = 0 otherwise. The weights, wm, are
specified to up-weight or down-weight a variant based on certain features.
Examples include weights that are based on allele frequencies, the degree
of evolutionary conservation or the functionality of the variations [Wessel
and Schork (2006); Schaid (2010a, 2010b); Price et al. (2010)]. We can use
the minor allele frequency of marker m, denoted as qm, to up-weight sim-
ilarities that are contributed by rare variants. Specifically, one can set a
moderate weight, such as wm = q
−3/4
m [Pongpanich, Neely and Tzeng (2012)]
or wm = q
−1
m [Tzeng et al. (2011)], to promote similarity attributed by rare
alleles, or use a more extreme weight, such as wm = (1− qm)24 [Wu et al.
(2011)], to target rare variants only.
The trait similarity, Zij , is quantified as follows. First, we define Yi =
H(Ti), where H(·) is an (unspecified) monotonic increasing transformation
function, such as the logarithm transformation Yi = log(Ti). Assume that
the conditional mean of Yi given the covariates and genes is E(Yi |Xi, gi) =
θ +XTi γ + gi, where θ is the intercept, gi is the multi-locus genetic effect
of person i, and γ is the K-dimensional covariate effect. Further, define
µ0i = θ +X
T
i γ. The trait similarity is defined as the product of the paired
residuals adjusting for the covariate effects, that is, Zij = (Yi−µ0i )(Yj −µ0j).
The expected value of the trait similarity is the covariance between the
transformed survival times of subjects i and j.
The gene-trait similarity regression has the form
E(Zij |Xi,Xj) = b× Sij, i 6= j.(3.1)
Just as in Tzeng et al. (2009, 2011), the regression has a zero intercept and
does not have the covariate term XiXj because the baseline and covariate
effects have been adjusted when defining Zij . This argument will become
more obvious from the viewpoint of variance components in the following
subsection. Under model (3.1), the overall association of a gene can be eval-
uated by testing the null hypothesis: b= 0.
3.2. Score test for the gene-level effect. We derive the score test statistic
based on the equivalence between the similarity regression and a mixed
model. This equivalence is demonstrated as follows. Consider a working
mixed model for the transformed survival time:
Yi =H(Ti) =X
T
i γ + gi + θ+ εi,(3.2)
where (g1, . . . , gn)
T ∼N (0, τS) with S = {Sij}ni,j=1, that is, the covariance
between gi and gj depends on the genetic similarity between subjects i and
j, and ε∗i ≡ θ+ εi, i= 1, . . . , n are independently and identically distributed
with a known distribution that is independent of Xi and gi. Given Xi and gi,
model (3.2) specifies a general class of linear transformation models [Cheng,
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Wei and Ying (1995)], which contains many popular survival models as spe-
cial cases. For example, when ε∗i follows the standard extreme value distribu-
tion, the linear transformation model becomes the PH model [Cox (1972)].
When ε∗i follows the standard logistic distribution, the linear transformation
model becomes the PO model [Bennett (1983)].
Under (3.2), the conditional expectation of the trait similarity between
individuals i and j (i 6= j) is
E(Zij |Xi,Xj) = cov(Yi, Yj |Xi,Xj) = cov(gi + ε∗i , gj + ε∗i )
= cov(gi, gj)
= τ × Sij.
Therefore, we have b= τ , that is, the regression coefficient in the similarity
regression (3.1) is the genetic variance component in the mixed model (3.2).
This motivates us to develop a score test for the variance component in the
working model. As shown in the Appendix, the score test statistics for τ = 0
can be written as
Qn =
1
n
(rˆ1, . . . , rˆn)S(rˆ1, . . . , rˆn)
T ,
where
rˆi =
∫ ∞
0
ωˆi(t)dMi(t; γˆ, Hˆ)
= δi
λ˙{Hˆ(T˜i)− γˆTXi}
λ{Hˆ(T˜i)− γˆTXi}
− λ{Hˆ(T˜i)− γˆTXi},
Mi(t;γ,H) = δiI(T˜i ≤ t)−
∫ t
0
I(T˜i ≥ s)dΛ{H(s)− γTXi},
ωˆi(t) = λ˙{Hˆ(t) − γˆTXi}/λ{Hˆ(t) − γˆTXi}, and S is as defined after equa-
tion (3.2). Here, λ(·) and Λ(·) are the hazard and cumulative hazard func-
tions of ε∗i , respectively, λ˙(·) is the first derivative of λ(·), and γˆ and Hˆ(·)
are the estimates of γ and H(·), respectively, in model (3.2) under the null
hypothesis: τ = 0. For example, if the PH model is imposed, that is, λ(u) =
λ˙(u) = eu, the estimators γˆ and Γˆ(·)≡ eHˆ(·) can be taken as the maximum
partial likelihood estimator and Breslow’s estimator, respectively. Under this
case, ωˆi(t)≡ 1 and rˆi = δi− Γˆ(T˜i) exp(−γˆTXi), that is, the martingale resid-
ual for the null model. If the POmodel is used, that is, λ(u) = eu/(1+eu) and
λ˙(u) = eu/(1 + eu)2, we have ωˆi(t) = 1/[1 + exp{Hˆ(t)− γˆTXi}]. In general,
γ and H(·) can be estimated using the martingale-based estimating equa-
tions [Chen, Jing and Ying (2002)] or the nonparametric maximum likeli-
hood estimation method [Zeng and Lin (2006)] for the semiparametric linear
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transformation model. In the Appendix, we show that under the null hypoth-
esis the test statistic, Qn, asymptotically follows a weighted χ
2 distribution
where the weights can be estimated consistently. The p-values can then be
calculated numerically using a resampling method or moment-matching ap-
proximations [Pearson (1959); Duchesne and Lafaye De Micheaux (2010)].
We note that the proposed score test can be robust to the misspecifica-
tion of the true survival model. As an illustration, consider the test derived
under the PH model. Based on the results for the robust inference of the
PH model [Lin and Wei (1989)], when the PH model is misspecified, the
maximum partial likelihood estimator, γˆ, and Breslow’s estimator, Γˆ(·), do
not converge to the true parameters but converge to some deterministic
values γ∗ and Γ∗(·) under certain regularity conditions. The corresponding
r∗i = δi−Γ∗(T˜i) exp(−XTi γ∗) is not a martingale residual but has a mean of
0 under the null hypothesis. Therefore, it can be shown that Qn converges
in distribution to a weighted χ2 distribution under the null hypothesis even
with model misspecification. As shown in our simulation studies, the pro-
posed score test derived under the PH model still gives correct type-I error
when the true model is the PO model. However, the power of the test de-
pends on the assumed working model. In general, the test derived under the
true risk model may have better power.
4. Results of the analysis of the VISP trial data. We now return to
the VISP trial to evaluate the association between the recurrent stroke risk
and the 9 candidate genes studied in Hsu, Sides and Mychalecky (2011).
In our analysis, we conducted a gene-based screening on the 9 genes us-
ing the low-dose samples. After removing loci with >1% of missingness
and subjects with missing genotypes, there were 969 individuals with 69
polymorphic SNPs under recessive coding. Of the 969 individuals, 86 ex-
perienced a recurrent stroke (i.e., 91.1% censoring). We used the proposed
similarity regression (referred to as SimReg) with inverse allele frequency
weights wm = q
−3/4
m , that is, the weight recommended in Pongpanich, Neely
and Tzeng (2012) when analyzing a mixture of common and rare variants.
We calculated the p-values of the SimReg statistics using the resampling
method. Specifically, we computed the nonzero eigenvalues, ξˆ1, . . . , ξˆd, of Σˆ
as defined in the Appendix. We generated 104 sets of (χ21,1, . . . , χ
2
1,d). Each
set consisted of d independently and identically distributed χ21 random vari-
ables. For each set, we calculated the value
∑d
k=1 ξˆkχ
2
1,k, and the 10
4 values
formed an empirical null distribution of the SimReg statistics. The Sim-
Reg p-value was the proportion of the generated null statistics that were
greater than the observed statistic. We performed SimReg analyses under
the PH model (referred to as SimReg-PH) and the PO model (referred to as
SimReg-PO). The performances of the SimReg methods were benchmarked
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Table 1
Results of the VISP genetic study
BHMT1 BHMT2 CBS CTH MTHFR MTR MTRR TCN1 TCN2
Numbers of SNPs 5 3 6 10 7 20 5 3 15
minP 0.3399 0.5968 0.3354 0.0918 0.9105 0.8933 0.6183 0.9764 0.0704
(Keff) (3.99) (2.83) (4.41) (8.35) (4.64) (10.64) (4.78) (2.77) (11.28)
Global 0.6457 0.7391 0.2669 0.0518 0.7819 0.9154 0.7363 0.9689 0.0457
KM 0.4863 0.6142 0.2386 0.0078 0.7094 0.8289 0.7289 1.0000 0.0075
SimReg-PH 0.5794 0.6402 0.1889 0.0073 0.6833 0.8835 0.5988 0.9845 0.0040
SimReg-PO 0.6136 0.6942 0.2877 0.0075 0.7807 0.9011 0.6422 0.9922 0.0052
The adjusted p-values for the gene were obtained using 1−(1−minimum raw p-value)Keff .
Significance is concluded by comparing the p-values with the Bonferroni threshold 0.05/9 =
0.0056, which accounts for the 9 gene analysis.
against three approaches: (a) the single SNP minimum p-value method using
the Cox PH model (referred to as minP), (b) the multi-SNP method using
the global test for survival under the PH model [Goeman et al. (2005)] as
implemented in the R-package globaltest (referred to as Global), and (c)
the multi-SNP method using the kernel machine [Lin et al. (2011)] as imple-
mented in the R-package KMTest.surv (referred to as KM) with 104 resam-
plings. Although the SimReg-PH test statistic is identical to the KM test
statistic, the results may be slightly different due to the different resampling
methods adopted to obtain the p-values. Specifically, in the KM method, the
score statistic was perturbed by multiplying i.i.d. normal random variables
to achieve the same limiting distribution of the test statistic. In SimReg-PH,
the weights in the limiting weighted χ2 distribution, that is, ξ1, . . . , ξd, were
consistently estimated and then the samples were directly generated from
the estimated weighted χ2 distribution based on a large number of i.i.d. χ21
random variables. The different resampling approaches also lead to different
computational burden. For example, using a 3.6 GHz Xeon Processor with
60 GB RAM with 104 resamplings, the system run-time of SimReg-PH was
<1/6 of KM in the VISP analysis, and the time difference became greater
with a larger number of resamplings. For the minP method, we fitted the
standard PH model to each SNP in a gene, took the smallest p-value and
calculated the adjusted p-value of a gene to correct for the multiple SNPs
using 1− (1−minimum raw p-value)Keff . The effective number of indepen-
dent tests, Keff , was estimated using the method of Moskvina and Schmidt
(2008) and accounts for the correlations in recessive coding of loci. As stud-
ied by Hsu, Sides and Mychalecky (2011), all analyses were considered under
the recessive mode and were adjusted for age, sex and race.
The p-values for each of the methods are shown in Table 1, and the p-
values are compared with the Bonferroni threshold adjusted for the 9 gene
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analyses, that is, 0.05/9 = 0.0056. SimReg-PH detected a significant associ-
ation between the recurrent stroke risk and TCN2 (i.e., p-value = 0.0040),
which strengthens the observation of differential survival between different
variants from the single SNP analysis. Gene CTH had the second small-
est p-value (0.0073), which did not pass the Bonferroni threshold but was
near the cutoff. These results also agree with the findings in the single SNP
analysis. The results of SimReg-PO are similar to those of SimReg-PH ex-
cept that the p-values are slightly larger, that is, p-value = 0.0052 for TCN2
and 0.0075 for CTH. On the other hand, the KM, Global and minP meth-
ods did not yield any significant findings. However, the smallest p-values
of the 9 genes were obtained for TCN2 (i.e., p-values of TCN2 are 0.0075
for KM, 0.0457 for Global and 0.0704 for minP). As expected, the results
of KM were very similar to those of SimReg-PH, except that the p-value of
TCN2 was slightly above the 0.0056 threshold. The smallest p-values for the
minP method were from the TCN2 SNP rs731991 with a raw Wald’s test
p-value of 0.0065. However, neither the raw minimum p-value (0.0065) nor
the adjusted p-value (0.0704) survived the significance threshold corrected
for multiple testing (0.0056). All methods also had CTH as the gene with
the second smallest p-value (i.e., p-values 0.0078 for KM, 0.0518 for Global,
and 0.00918 for minP).
Next, we assessed the prediction performance of Cox PH models built
with and without TCN2 using the procedure described in Li and Luan
(2005). Specifically, we randomly divided the samples into a training set
(n = 646) and a testing set (n = 323). Based on the training set, we fitted
the Cox PH regression with two models: Model 1 included only the baseline
covariates (age, sex and race), that is, no genetic information, and model 2
included the baseline covariates plus the top 7 principal components (PCs)
of TCN2 SNPs that explained 95% of the variations. The PCs were used in-
stead of the 15 original genotypes because of the high linkage disequilibrium
among them. Based on the fits of the PH model from the training set, we
obtained the risk scores of every subject under each model and computed
the medians of the risk scores. We also computed the risk scores for the
testing set using the estimated coefficients from the training set. Next, we
divided the subjects into 2 risk groups: high-risk and low-risk. Individuals
with a risk score higher/lower than the median risk scores obtained from
the training data comprised the high-risk/low-risk group. Finally, we plot-
ted the Kaplan–Meier curves for the 2 risk groups in the training data and
the two risk groups in the testing data separately and obtained the p-values
of the corresponding log-rank tests. The results are given in Figure 2. As
expected, the p-values for both models under the training set were very sig-
nificant. However, only model 2 is significant (p-value is 0.048) under the
testing set. This result implies that TCN2 gives a more accurate prediction
of the risk for recurrent stroke.
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Fig. 2. The Kaplan–Meier survival curves for the two risk groups of patients.
Vitamin supplements have been identified as a potential treatment for
vascular diseases. The beneficial effects of vitamin supplements on stroke
recurrence are not yet fully understood. In VISP, vitamin supplements did
not show an effect on the recurrent stroke risk during the 2 years of follow-
up. However, we found that genetic variants, such as SNPs in TCN2, were
associated with the recurrent stroke risk in the low-dose arm. This finding
is consistent with the literature. TCN2 was previously found to be asso-
ciated with ischemic stroke risk [Low et al. (2011); Giusti et al. (2010)]
and premature ischemic stroke risk [Giusti et al. (2010)]. It has been re-
ported that TCN2 interferes with the intracellular availability of vitamin
B12 [von Castel-Dunwoody et al. (2005)]. The gene is associated with plasma
homocysteine levels and affects the proportion of vitamin B12 bound to
transcobalamin [Afman et al. (2003)]. It is suspected that SNPs on the
genes coding for enzymes involved in the methionine metabolism have been
suspected to be associated with hyperhomocysteinaemia, which can result
in occurrence of stroke [Giusti et al. (2010)]. Our significant findings in the
low-dose arm suggest that there may be an interaction between TCN2 and
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B12 supplementation, a finding that warrants further studies. The findings
lead to a hypothesis that there may be one specific combination of genotypes
of TCN2 that is more efficient at transporting B12 and thus impacts the
effectiveness of cofactor therapy on recurrent stroke risk. A functional study
is being planned to localize possibly independent regions of association and
determine their function.
Besides TCN2, CTH is marginally associated with recurrent stroke risk
in the low-dose arm. It encodes cystathionine gamma-lyase, which is an en-
zyme that converts cystathionine to cysteine in the trans-sulfuration path-
way [Wang et al. (2004)]. It may be a determinant of plasma Hcy concen-
trations, which may increase the risk of recurrent stroke because of arterial
disease. It is worth further study as well.
5. Simulation studies. We performed simulations to assess the validity
and effectiveness of the proposed SimReg methods based on the 15 SNPs
in TCN2 of the 969 VISP low-arm samples. The rarest minor allele fre-
quency (MAF) is approximately 3%. We generated genotypes of n indi-
viduals by randomly sampling with replacement from the 15-SNP geno-
types of the 969 samples. For individual i, we generated the covariate,
Xi, from N(0,1). We generated the survival time, Ti, based on the ge-
netic and covariate information under two models: the PH model and the
PO model. Specifically, for the PH model, log(Ti) =−(Xi +
∑
ℓ γℓGℓi) + ε∗i ,
where ε∗i follows the standard extreme value distribution; for the PO model,
log{exp(Ti)− 1}=−(Xi+
∑
ℓ γℓGℓi) + ε∗i , where ε∗i follows the standard lo-
gistic distribution. The value of Gℓi is determined by the genotypes at the
causal locus ℓ and the mode of inheritance. For example, if A is the causal
allele at locus ℓ, then Gℓi = 2,1 and 0 for genotypes AA, Aa and aa, respec-
tively, under an additive mode. Under a dominant mode, G·i = 1,1 and 0,
respectively. Under a recessive mode, G·i = 1,0 and 0, respectively. For type
I error analysis, no SNPs were set to be causal, that is, γℓ was set to be 0
for all ℓ. For power analysis, we selected 3 SNPs with different MAFs and
LD patterns as causal loci from the 15 SNPs in TCN2 and referred to them
as SNP R, SNP U and SNP C. The MAFs are 0.036 (rare) for SNP R, 0.132
(uncommon) for SNP U and 0.419 (common) for SNP C. The average R2’s
between a causal locus and the remaining loci are 0.002 (low) for SNP R,
0.003 (low) for SNP U and 0.216 (high) for SNP C. The specific values of γℓ’s
are given in Table 2 for each scenario under different inheritance modes and
censoring rates. The values were set to consider 1, 2 and 3 causal loci in the
gene and to consider causal loci that have either the same or different effect
sizes (e.g., rarer variants with larger effect sizes). All of the power scenarios
assumed linear additive effects of the causal loci, which favors the linear
random effects model (e.g., Global) and can be used to examine the utility
of using the nonlinear IBS function to capture the multi-marker effects.
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Table 2
Effect sizes for power analyses
Additive and dominant Recessive
15%∗ 40% 90% 15% 40% 90%
n= 500n= 500n= 1000 n= 1000n= 1000n= 1000
ScenarioCausal SNPs (MAF) Effect size (γR, γU , γC) Effect size (γR, γU , γC)
1 R (0.036) (1.5, 0.0, 0.0) (4.0, 0.0, 0.0)
2 U (0.132) (0.0, 1.0, 0.0) (0.0, 3.0, 0.0)
3 C (0.419) (0.0, 0.0, 0.3) (0.0, 0.0, 0.3)
4 R, U (0.6, 0.6, 0.0) (4.0, 4.0, 0.0)
5 R, U (0.6, 0.4, 0.0) (2.5, 2.0, 0.0)
6 R, C (0.3, 0.0, 0.3) (0.3, 0.0, 0.3)
7 R, C (0.6, 0.0, 0.2) (2.5, 0.0, 0.2)
8 U, C (0.0, 0.3, 0.3) (0.0, 0.3, 0.3)
9 U, C (0.0, 0.4, 0.2) (0.0, 2.0, 0.2)
10 R, U, C (0.3, 0.3, 0.3) (0.3, 0.3, 0.3)
11 R, U, C (0.6, 0.4, 0.2) (2.5, 2.0, 0.2)
∗censoring proportion.
We generated the censoring time, Ci, from Unif(0, c), where c is uniquely
chosen for each of 3 censoring rates: 15%, 40% and 90%. Specifically, we set
c= 6.7, 2.0 and 0.2 for censoring rates of 15%, 40% and 90%, respectively.
The sample sizes, n, were 500 for the 15% and 40% censoring rates under the
additive and dominant modes. For the 90% censoring rate under the additive
and dominant modes and all censoring rates under the recessive mode, n=
1000. Each scenario was analyzed using SimReg (PH and/or PO), minP,
Global and KM. SimReg-PH and KM have identical test statistics but used
different resampling approaches to obtain p-values. Because both resampling
approaches are asymptotically equivalent, we expect minor differences in
finite sample performance between SimReg-PH and KM. In all analyses, the
causal loci were excluded.
5.1. Results of type I error analyses. We first examined the performance
of the proposed SimReg-PH model. Table 3 displays the type I error rates
of different methods when the survival times were generated from the PH
model. The results were based on 105 replications except that KM was based
on 5× 104 replications due to computational cost. In each replication, the
p-values of SimReg-PH were obtained from 5× 105 resamplings. We report
the type I error rates evaluated at the nominal levels of 5× 10−2, 5× 10−3
and 5 × 10−4. The type I error rates obtained by SimReg-PH remained
around the nominal levels. However, the deviations were larger for α= 5×
10−4, mainly due to fewer resampled statistics observed on the extreme
tail. In particular, for the low censoring proportion (i.e., 15%), the type I
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Table 3
Type I error rates for survival time generated from the PH model
Additive Dominant Recessive
Analyzed under 15% 40% 90% 15% 40% 90% 15% 40% 90%
PH model (n= 500) (n= 500) (n= 1000) (n= 500) (n= 500) (n= 1000) (n= 1000) (n= 1000) (n= 1000)
α= 5× 10−2 (Rates shown on the scale of 10−2)
minP 4.89 4.85 4.44 4.92 4.84 4.16 7.63 7.46 7.25
Global 2.73 2.71 2.72 3.01 2.99 2.96 2.75 2.74 2.73
KM 5.07 5.11 4.73 5.10 5.17 4.81 5.12 4.97 4.78
SimReg-PH 5.11 5.10 4.79 5.15 5.11 4.83 5.21 5.04 5.01
α= 5× 10−3 (Rates shown on the scale of 10−3)
minP 6.52 6.22 5.50 6.13 5.44 4.39 17.09 17.62 19.21
Global 2.82 2.65 2.67 2.98 2.74 2.86 2.61 2.50 2.59
KM 5.18 4.86 4.02 5.26 4.86 4.28 5.40 5.54 4.96
SimReg-PH 5.18 4.91 4.15 5.22 5.03 4.38 5.84 5.20 5.96
α= 5× 10−4 (Rates shown on the scale of 10−4)
minP 8.6 8.1 6.8 8.0 7.0 6.2 48.4 47.9 60.3
Global 2.9 3.9 2.7 4.0 3.2 2.4 3.1 2.9 2.8
KM 5.8 5.2 2.8 6.8 5.8 4.4 8.4 4.4 6.6
SimReg-PH 7.1 5.7 2.7 6.9 5.4 3.2 8.0 4.6 8.1
The type I error rates are shown on the scale of 102, 103, and 104 for nominal level at 0.05, 0.005, and 0.0005, respectively. The survival
times were generated from the PH model and were analyzed using different approaches under the PH model. The results were based on
105 replications except that the results for KM were based on 5× 104 replications.
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error rates were slightly inflated, while for the high censoring proportion
(i.e., 90%), the type I error rates became a little conservative when α =
5× 10−4. Nevertheless, the overall results suggest that the SimReg-PH test
maintained an appropriate size, which confirms the validity of the derived
null distribution of the test statistic, Qn. As expected, the type I error rates
obtained by KM were very similar to SimReg-PH. The type I error rates
obtained by the Global test are overly conservative; similar behavior has
been reported in the literature [Zhong and Chen (2011)]. The minP method
had correct type I error rates under additive and dominant modes. However,
the method had inflated type I error rates under the recessive mode, and
the inflation was more severe with smaller α. Under the recessive mode,
the Bonferroni corrected p-values obtained by replacing Keff with the total
number of SNPs also yielded inflated type I error rates. Specifically, the
empirical type I error rates for 15%, 40% and 90% censoring are (0.0627,
0.0687, 0.0608) for α= 5×10−2, (0.0145, 0.0152, 0.0163) for α= 5×10−3 and
(0.0042, 0.0041, 0.0053) for α= 5×10−4, respectively. The anti-conservation
appears to be somewhat related to the rare recessive loci; when the rare loci
are excluded from the analysis, the empirical type I error rate became closer
to the nominal level (data not shown). However, such an exclusion strategy
might give uninformative results because the relevant signals were excluded
from the analysis.
Table 4 displays the type I error rates when the survival times were gen-
erated from the PO model. Both SimReg-PH and SimReg-PO were imple-
mented. The results were based on 5000 replications, and the type I error
rates were calculated at the nominal level of 0.05. The type I error rates
for both SimReg-PO and SimReg-PH were close to 0.05 independent of the
inheritance mode and the censoring proportions. These results show the va-
lidity of the SimReg-PO tests and the robustness of the SimReg-PH tests.
Though not performed, KM is expected to have the same robustness as
SimReg-PH. As seen previously, the Global test had conservative type I er-
ror rates, but the magnitude of conservation is less than that seen in Table 3.
The minP method yielded slightly inflated type I error rates for the additive
and dominant modes with low censoring proportion (i.e., 15%). As before,
it yielded inflated type I error rates for the recessive mode.
5.2. Results of power analyses. The power analyses were performed us-
ing the settings specified in Table 2. The results were based on 100 replica-
tions under each scenario. Figure 3 shows the power when the survival times
were generated from the PH model. We first consider the additive mode.
When one large-effect causal locus has low MAF and low LD with the other
markers (e.g., Scenarios 1, 5 and 11), minP tends to have the highest power
independent of the censoring proportion. The good performance of minP
is not unexpected in these scenarios because the overall association of the
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Table 4
Type I error rates for survival time generated from the PO model
Additive Dominant Recessive
15% 40% 90% 15% 40% 90% 15% 40% 90%
(n= 500) (n= 500) (n= 1000) (n= 500) (n= 500) (n= 1000) (n= 1000) (n= 1000) (n= 1000)
minP 0.0584 0.0548 0.0444 0.0560 0.0492 0.0410 0.0798 0.0774 0.0740
Global 0.0358 0.0320 0.0256 0.0352 0.0332 0.0266 0.0342 0.0312 0.0250
SimReg-PH 0.0488 0.0496 0.0464 0.0492 0.0504 0.0478 0.0526 0.0518 0.0480
SimReg-PO 0.0446 0.0486 0.0468 0.0452 0.0496 0.0508 0.0544 0.0492 0.0490
The survival times were generated from the PO model and were analyzed using different approaches under the PO model or the PH
model (to examine the impact of model misspecification). The results were based on 5000 replications.
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Fig. 3. Power when the survival times are generated from the PH model.
gene was driven by a single large-effect locus, for which the majority of the
other SNPs did not carry much information. As a result, there is no power
gain when borrowing information from other SNPs, which is what SimReg-
PH does. However, the power gain of minP over other methods generally
diminishes as the number of causal loci increases (e.g., Scenarios 5 to 10). In
scenarios where the marker set is not dominated by a single causal locus of
low MAF and low LD, SimReg-PH showed comparable or higher power. As
expected, KM had near identical power as SimReg-PH in all scenarios. In
most scenarios, the Global test produces the least amount of power largely
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Fig. 4. Power when the survival times are generated from the PO model.
due to the over-conservative test size. The overall performance under the
dominant mode has a similar trend to that of the additive mode. However,
the power of SimReg-PH is comparable to or better power than the power of
minP in more cases under the dominant mode than under the additive mode.
For the recessive mode, SimReg-PH appears to have better power than the
Global test. We did not perform a power analysis for minP because the type
I error rates were inflated.
Figure 4 shows the power performance when the survival times were gen-
erated from the PO model. The power obtained using SimReg-PO is similar
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to or better than the power obtained using SimReg-PH, indicating that effi-
ciency is gained when the correct model is used. The power gain of SimReg-
PO is more substantial when the censoring proportion is low to medium,
and the power is comparable to or better power than the minP power in
some of those difficult cases, such as Scenario 1.
6. Discussion. In this work we extended the similarity regression (Sim-
Reg) approaches, which have shown effectiveness in modeling marker-set
effects on binary and continuous outcomes, to survival models to facilitate
the assessment of gene or pathway effects on drug responses. The genetic
effect is evaluated by assessing the association between the IBS status of a
pair of individuals and the covariance of their survival times. We derived the
equivalence between the similarity survival regression and a random effects
model. The equivalence facilitates the derivation of the score test statistics
and unifies the current variance component-based methods. Specifically, the
KM approach [Lin et al. (2011)] is equivalent to SimReg-PH when the same
kernel function is used to quantify the genetic similarity, Sij . The Global
test [Goeman et al. (2005)] can be viewed as a special case of SimReg-
PH with Sij =
∑
mg
T
m,igm,j (i.e., the linear kernel). However, the results of
Global and SimReg-PH with linear kernels may be different because differ-
ent approaches were used to derive the asymptotic distributions of the test
statistics. Compared to these existing gene-based approaches, our proposed
method has the generality to incorporate a variety of risk models in the class
of linear transformation models, and we explicitly constructed the SimReg
tests under the PH model and the PO model in this work. We also proposed
a resampling approach to obtain the p-values that improves the computa-
tional efficiency. Finally, we showed that the derived inference procedure is
robust against the misspecification of the risk model, which is an attractive
feature because the underlying risk model is often unknown. Through sim-
ulations, we showed that the power of the SimReg method is comparable to
or higher than the power of the minP and Global methods across various
scenarios. We also verified that the SimReg-PH test statistics remain valid
even if the risk model is misspecified.
In the data application on the VISP study, we illustrated how SimReg
can be used to search for genes or pathways that are associated with a time-
to-event outcome and confirmed previous findings using this gene-based ap-
proach with statistical significance. Although we focused our method devel-
opment and demonstrated its utility based on pharmacogenetics studies, the
proposed method is applicable to other genetic clinical researches or obser-
vational studies with time-to-event outcomes. For a pharmacogenetic study
with sample sizes 1000, such as the VISP trial, 1000 runs of the SimReg anal-
yses took ≤1 hour to complete on an Intel Xeon 3.33 GHz machine with 12
Gb RAM using one processing core. We expect a gene-based whole genome
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analysis on ∼20K genes should be completed in a day using a comparable
computing facility. We implemented the proposed methods in R and made
it available at the authors’ websites. We are incorporating the software into
the SimReg R package.
Motivated by the data application where the risk variant acted reces-
sively, we further investigated the behavior of the gene-based approaches
under different modes of inheritance. We found that all of the studied gene-
based methods performed appropriately under the additive and dominant
modes. However, caution should be used when performing the minimal p-
value approaches under the recessive mode; the minimal p-value approaches
had severely inflated type I error rates. The inflation might be related to the
extremely rare recessive loci. However, excluding those rare recessive loci is
suboptimal because the important signals can be artificially removed and
lead to power loss. In contrast, the global test and the similarity regression
are not vulnerable to such a situation and appear to be more suitable options
given their reasonable performance under the recessive mode.
This work focused on assessing the genetic main effect on drug response
in an effort to understand how individual variation affects drug efficacy and
toxicity. In pharmacogenetics and personalized medicine, one major topic is
to study if the genetic effects are modified by treatments and how the effects
differ across treatment options. As observed in the VISP genetic studies, the
effect of TCN2 on recurrent stroke risk is restricted to the low-dose treat-
ment. An analysis stratified by treatments allows for the evaluation of such
heterogeneous effects between different treatment groups, but its efficiency
can be further improved by incorporating the gene-treatment interaction
in the regression model. Such an extension is not straightforward because
the calculation of the score test requires the variance component estimates
for the genetic main effect under a mixed-effects survival model. We are
developing further extensions of SimReg to incorporate interaction effects.
APPENDIX
Derivation of the score statistic Qn: Given the working mixed model
H(Ti) = γ
TXi + gi + ε
∗
i , the log-likelihood function of the observed data
can be written as
ln(γ,H, τ)
= log
∫
· · ·
∫ n∏
i=1
[λ{H(T˜i)− γTXi − gi}]δi
× e−Λ{H(T˜i)−γTXi−gi}fG(g1, . . . , gn)dg1 · · ·dgn,
where λ and Λ are the specified hazard and cumulative hazard functions
of ε∗i , and fG(g1, . . . , gn) is the joint density of g1, . . . , gn, that is, a mul-
tivariate normal density with mean 0 and variance–covariance matrix τS.
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Consider the variable transformation (g∗1 , . . . , g
∗
n)
′ = τ−1/2S−1/2(g1, . . . , gn)
′,
where S = S1/2S1/2. Then (g∗1 , . . . , g
∗
n)
′ follows a standard multivariate nor-
mal distribution. The result leads to
ln(γ,H, τ)
= log
∫
· · ·
∫ n∏
i=1
[λ{H(T˜i)− γTXi − τ1/2S1/2g∗i }]δi
× e−Λ{H(T˜i)−γTXi−τ1/2S1/2g∗i }
× f∗G(g∗1 , . . . , g∗n)dg∗1 · · ·dg∗n,
where f∗G is the density for the standard multivariate normal distribution.
After some algebra, we have
1
n
∂ln(γ,H, τ)
∂τ
∣∣∣∣
τ=0
=
1
2n
(r1, . . . , rn)S(r1, . . . , rn)
T
+
1
2n
n∑
i=1
[
λ¨(ei)λ(ei)−{λ˙(ei)}2
λ2(ei)
− λ˙(ei)
]
sTi si,
where ei =H(T˜i)− γTXi, λ¨(·) is the second derivative of λ(·), si is the ith
row of the matrix S1/2 and ri =
∫∞
0 λ˙{H(t)−γTXi}/λ{H(t)−γTXi}dMi(t;
γ,H). The equality in the above equation is obtained by first taking the
derivative of ln(γ,H, τ) with respect to τ and then deriving its limit as
τ → 0 using L’Hoˆpital’s rule. Note that the first term on the right-hand
side of the above equation is nonnegative, and the second term converges in
probability to a constant as n goes to infinity. In addition, under the null
hypothesis, ri’s have expectation of 0 at the true values of γ and H because
they are martingale integrations. Therefore, if the null hypothesis is correct,
the first term in the summation should be close to 0. This result motivates
us to consider a score test and reject the null hypothesis when the score
(1/n)∂ln(γˆ, Hˆ, τ)/∂τ |τ=0 is bigger than some value, where γˆ and Hˆ are the
estimates of γ and H , respectively, under the null model. It is asymptotically
equivalent to consider the test statistic Qn = n
−1(rˆ1, . . . , rˆn)S(rˆ1, . . . , rˆn)
T
and reject the null hypothesis when Qn > cα, where cα is the critical value
for a level-α test.
Null distribution of the score statistic Qn: Here, we consider the estimators
γˆ and Hˆ(·) obtained via the martingale-based estimating equations for the
standard linear transformation model [Chen, Jin and Ying (2002)] under the
null hypothesis. Note that Qn = (n
−1/2
∑n
i=1 rˆisi)
T (n−1/2
∑n
i=1 rˆisi). Let γ0
and H0 denote the true values of γ and H , respectively, in the null model.
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Based on the derivations given in Chen, Jin and Ying (2002), we have the
following asymptotic representations:
√
n(γˆ − γ0) =−A−1 1√
n
n∑
i=1
∫ ∞
0
{Xi − µX(t)}dMi(t;γ0,H0) + op(1),
√
n{Hˆ(t)−H0(t)}=−b1(t)TA−1 1√
n
n∑
i=1
∫ ∞
0
{Xi − µX(t)}dMi(t;γ0,H0)
+
1√
n
n∑
i=1
∫ t
0
φ(t, s)dMi(s;γ0,H0) + op(1).
The definitions of A, µX(·), b1(·) and φ(·, ·) can be found in Chen, Jin and
Ying (2002). By the Taylor expansion, we can show that
1√
n
n∑
i=1
rˆisi→d N(0,Σ),
as n→∞, where Σ =E(ψiψTi ) and
ψi =
[
δi
λ˙{H0(T˜i)− γT0 Xi}
λ{H0(T˜i)− γT0 Xi}
− λ{H0(T˜i)− γT0 Xi}
]
si
− (B1 −B2)A−1
∫ ∞
0
{Xi − µX(t)}dMi(t;γ0,H0)
−
∫ ∞
0
b2(t)dMi(t;γ0,H0).
Here
B1 = lim
n→∞
1
n
n∑
i=1
siX
T
i [λ˙{H0(T˜i)− γT0 Xi}
− δi(λ¨{H0(T˜i)− γT0 Xi}λ{H0(T˜i)− γT0 Xi}
− (λ˙{H0(T˜i)− γT0 Xi})2)
/(λ{H0(T˜i)− γT0 Xi})2],
B2 = lim
n→∞
1
n
n∑
i=1
sib1(T˜i)
T [λ˙{H0(T˜i)− γT0 Xi}
− δi(λ¨{H0(T˜i)− γT0 Xi}λ{H0(T˜i)− γT0 Xi}
− (λ˙{H0(T˜i)− γT0 Xi})2)
/(λ{H0(T˜i)− γT0 Xi})2],
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b2(t) = lim
n→∞
1
n
n∑
i=1
siI(T˜i ≥ t)
× φ(T˜i, t)[λ˙{H0(T˜i)− γT0 Xi}
− δi(λ¨{H0(T˜i)− γT0 Xi}λ{H0(T˜i)− γT0 Xi}
− (λ˙{H0(T˜i)− γT0 Xi})2)
/(λ{H0(T˜i)− γT0 Xi})2].
Therefore, Qn converges in distribution to a weighted χ
2 distribution:∑d
k=1 ξkχ
2
1,k, where χ
2
1,1, . . . , χ
2
1,d are d independently and identically dis-
tributed χ2 random variables with degree freedom of 1, and ξ1, . . . , ξd are
the d nonzero eigenvalues of the matrix Σ. To obtain the critical value, cα,
of the limiting weighted χ2 distribution, we use a numerical method. Specif-
ically, we first obtain a consistent estimator, Σˆ, of Σ using the usual plug-in
method and compute the nonzero eigenvalues ξˆ1, . . . , ξˆd of the matrix Σˆ.
Next we generate a large set (e.g., 10,000 sets) of independent and identi-
cally distributed random variables χ21,1, . . . , χ
2
1,d. For each set of χ
2 random
variables, we compute
∑d
k=1 ξˆkχ
2
1,k. We can then estimate cα by the upper
α-quantile of
∑d
k=1 ξˆkχ
2
1,k’s and the associated p-value of the score test can
be computed accordingly.
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